Long-term comparative efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and chronic kidney disease: A nationwide observational study
Heart Rhythm · 2026-06
DOI: 10.1016/j.hrthm.2026.06.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart Rhythm, 2026-06. Verfasst von Yeela Talmor-Barkan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Isra…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Patients with atrial fibrillation (AF) and chronic kidney disease (CKD) face an increased risk of both thromboembolic and bleeding events, making anticoagulation management challenging. OBJECTIVE: This study aimed to compare the efficacy and safety of direct oral anticoagulants (DOACs), warfarin, and no oral anticoagulation (OAC) in patients with AF and CKD. METHODS: Using data of 18,980 AF patients with CKD from Clalit database, we compared OAC vs no OAC and DOACs vs warfarin. Primary endpoints were composite-safety (intracranial hemorrhage, gastrointestinal bleeding) and efficacy (ischemic stroke, myocardial infarction, embolism, all-cause mortality). RESULTS: OAC therapy was associated with a lower risk of the primary composite efficacy outcome compared with no OAC (hazard ratio [HR]: 0.57, 95% confidence interval [CI]: 0.52-0.62), driven by reduced all-cause mortality (HR: 0.32, 95% CI: 0.29-0.36), with no significant differences in thromboembolic events or bleeding outcomes. In the comparison of DOACs vs warfarin, warfarin was associated with higher rates of composite bleeding (HR: 0.67, 95% CI: 0.5-0.89) and intracranial hemorrhage (HR: 0.51, 95% CI: 0.32-0.8). DOACs were associated with a lower risk of the primary composite efficacy outcome (HR: 0.84, 95% CI: 0.74-0.95), with no significant differences in ischemic stroke. Among appropriately anticoagulated patients, safety differences between DOACs and warfarin were no longer significant (composite bleeding HR: 0.87, 95% CI: 0.52-1.47); however, DOACs remained associated with fewer primary efficacy events (HR: 0.75, 95% CI: 0.60-0.94). CONCLUSION: In patients with AF and CKD, OAC therapy improved efficacy outcomes without increasing bleeding risk. DOACs were more effective and safer than warfarin, supporting their use as the preferred anticoagulant in this high-risk population. Appropriate dosing and therapeutic monitoring are essential to maximize benefits and minimize bleeding complications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; Department of Computer Science and Applied Mathematics, Weizmann I…
- Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
- Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. Electronic address: Eran.Sega…
- Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel; Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel; Department of Molecular Neuroscie…
Zitieren
APA
Talmor-Barkan, Y., Kornowski, R., Witberg, G., Skalsky, K., Kalka, I., Rossman, H., Segal, E., & Yacovzada, N. (2026). Long-term comparative efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and chronic kidney disease: A nationwide observational study. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2026.06.020
Vancouver
Talmor-Barkan Y, Kornowski R, Witberg G, Skalsky K, Kalka I, Rossman H, et al. Long-term comparative efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and chronic kidney disease: A nationwide observational study. Heart Rhythm. 2026. doi:10.1016/j.hrthm.2026.06.020
BibTeX
@article{TalmorBarkan2026,
author = {Talmor-Barkan, Yeela and Kornowski, Ran and Witberg, Guy and Skalsky, Keren and Kalka, Iris and Rossman, Hagai and Segal, Eran and Yacovzada, Nancy},
title = {Long-term comparative efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and chronic kidney disease: A nationwide observational study},
journal = {Heart Rhythm},
year = {2026},
doi = {10.1016/j.hrthm.2026.06.020}
}
EUVIMED